Abstract
Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n=115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research in this study was supported by National Institute of Health (NIH) grants R01AI121920, U54 NS105539 and U19 AI142733 to Derya Unutmaz
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1) IRB# SUNY:269846. The patients were recruited at SUNY Downstate, NY and processed and biobanked at Amerimmune, Fairfax VA; 2) IRB# STUDY00000640 Convalescent plasma was collected at Cedars Sinai Medical Center according to FDA protocol (https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma#Collection%20of%20COVID-19). The source of the convalescent plasma was volunteer blood donors who were recovered from COVID-19. Donors met routine blood donor eligibility requirements established by the FDA and had a prior SARS-CoV-2 infection documented by a laboratory test for the virus during illness, or antibodies to the virus after recovery of suspected disease. All donors were least 28 days from either resolution of COVID-19 symptoms or diagnosis, whichever was longer; 3) IRB# 20-186-1. UConn Healthcare workers who tested positive for the virus by PCR were recruited and samples banked for future testing. 4) IRB#: 17-JGM-13-JGM or 16-JGM-06-JGM. De-identified control subjects (n=20) used were previously frozen (more than a year ago) samples obtained from healthy controls or determined to be CoV-2 PCR negative (IRB SUNY:269846).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We now revised our manuscript according to reviewers critiques. We performed new experiments, increased our subject number to 115 and also added more negative controls, added several new figures (Figures 1D, 1E, 5E, Supplementary Figures 1B and 5) and revised others (Figures 2, 3F, 4C, 4D, 5B, 5C, 5D, 6, Supplementary Figures 1A, 1B, 1C, 2A, 3, 4, and 5) and extensively revised the manuscript accordingly. All new significant additions or edits to the text are yellow marked to make it easier to see the changes. Together, we believe these revisions further confirmed most of our key points in the original submission and greatly enhanced the impact of our findings.
Data Availability
The source data for the Figures along with the Supplementary Figures presented in this paper are available upon request.
